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Cholesterolrited metabolic disorders caused by defects in awide spectrum of lysosomal and a
few non-lysosomal proteins. In most cases a single type of primary storage material is identiﬁed, which has
been used to name and classify the disorders: hence the terms sphingolipidoses, gangliosidoses,
mucopolysaccharidoses, glycoproteinoses, and so forth. In addition to this primary storage, however, a host
of secondary storage products can also be identiﬁed, more often than not having no direct link to the primary
protein defect. Lipids – glycosphingolipids and phospholipids, as well as cholesterol – are the most ubiquitous
and best studied of these secondary storage materials. While in the past typically considered nonspeciﬁc and
nonconsequential features of these diseases, newer studies suggest direct links between secondary storage and
disease pathogenesis and support the view that understanding all aspects of this sequestration process will
provide important insights into the cell biology and treatment of lysosomal disease.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Lysosomal diseases represent a complex family of nearly 60
inherited metabolic disorders linked by defects in speciﬁc proteins
critical for lysosomal function [1]. A majority of these disorders are
severe, and many are characterized by a progressive neurodegenera-
tive and mental deterioration. Collectively, their estimated incidence
ranges between 1/5000 to 1/9000 live births. Most are due to the
deﬁciency of a speciﬁc hydrolytic lysosomal enzyme (or its ancillary
“activator” protein) directly responsible for degradation of complex
molecules, or of a lysosomal membrane transport protein involved in
egress from lysosomes of one of the ﬁnal products. They can also be
the consequence of a multiple deﬁciency of lysosomal enzymes due to
a defect in ER- and Golgi/TGN-associated enzymes involved in a
commonprocessing/trafﬁcking step. Finally they can be due to defects
in soluble or transmembrane lysosomal proteins of still partially
unclear function believed essential for substrate degradation, vesicle
fusion, pH regulation, substrate salvage, trafﬁcking/sorting of lipids
and proteins and so forth. Indeed, defects in no less than 50 different
proteins have been implicated to date as causing lysosomal dysfunc-
tion, and new proteins linked to lysosomal disease continue to be
identiﬁed. Defects in lysosomal function typically lead to lysosomal
storage and in the case of single hydrolytic enzyme deﬁciencies,
primary storage materials can usually be readily identiﬁed. Yet iny).
ll rights reserved.reality the storage process affecting cells is far more complex than
suggested by this simple one enzyme-one substrate relationship, with
multiple substrate storage being typically characteristic. While in
some cases this heterogeneity can be explained by a metabolic link,
with multiple compounds sensitive to the same enzyme, most
examples of secondary storage appear unrelated to this and more
likely arise through other, often still poorly deﬁned mechanisms.
Importantly, considerable evidence suggests that secondary storage
compounds can themselves be actively involved in disease pathogen-
esis. In order to gain a full understanding of the cell biology and
pathogenesis of lysosomal disease, it is essential to understand the
basis for these complexmetabolic events leading tomultiple substrate
storage. Various types of compounds may accumulate. Some of them
are particularly important in certain diseases, such as the c-subunit of
mitochondrial ATP synthase or saposins in ceroid lipofuscinoses,
whereas others are more ubiquitous, among which lipids constitute
the most common and best studied category and are therefore the
focus of this review.
2. Patterns of secondary lipid accumulation
Secondarily accumulating lipids in lysosomal disease can belong to
any of the major classes, cholesterol, phospholipids and glyco-
sphingolipids (GSLs), with different patterns in brain and in visceral
organs often occurring in the same disease. Most of the changes have
been initially described using biochemical methods, ﬁrst in tissues of
patients and then in various animal models. More recently, studies
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cholesterol have provided new insights into the cellular site of
accumulation. Ancillary studies in living cells have also been useful to
pinpoint some secondary metabolic blocks.
2.1. Glycosphingolipids and free sphingoid bases
2.1.1. Glycosphingolipids in brain
A secondary accumulation of GM2 and GM3 gangliosides is a
common feature associated with neuropathology in a number of
lysosomal storage diseases, principally Niemann-Pick diseases and
mucopolysaccharidoses, but also prosaposin deﬁciency, as well as
some glycoproteinoses and ceroid lipofuscinoses. In human brain,
GM2 and GM3 are normally veryminor components and constitute no
more than 1–2% of the total gangliosides. Their proportion is even
smaller in normal mouse brain. The largest increase, affecting both
gangliosides but more particularly GM2, has been found in autopsy
brain of patients with Niemann-Pick disease type A (but not type B)
[2–7], and in patients with Niemann-Pick C disease (NPC) [7–13]. Very
similar changes have been found in sphingomyelinase-deﬁcient and in
NPC1- or NPC2-deﬁcient models in mice or cats [14,15]. For either
Niemann-Pick A or C diseases, abnormalities were absent in human
brain at the foetal stage [16–18]. However, for both diseases,
ganglioside storage occurs early, as shown by studies in mutant
mice. In the npc1nih mouse brain, abnormal levels of GM2 were
already present in 10-day old animals, with a later increase of GM3
[15; L. Verot, P. Lobel and MT Vanier, unpublished]. Abnormalities
were observed for both GM2 and GM3 in the brain of a 3-month old
child with NPC [13]. Pronounced abnormalities have also been
reported in prosaposin deﬁciency (a combined defect in the
sphingolipid activator proteins saposins A, B, C and D), both in
humans and the mouse model [19,20], and very recently in the
cathepsin D deﬁcient mouse (model of CLN10) [21]. In Niemann-Pick
A and C as well as in prosaposin deﬁciency, the ganglioside increase is
accompanied by a prominent increase in glucosylceramide and
lactosylceramide [9,13,18–20]. Clearly abnormal levels of GM3 and
GM2, although signiﬁcantly lower, are further seen in mucopolysac-
charidosis (MPS) type III brain, in human, mice and emu bird [22–27],
and similar but evenmilder changes occur inMPS I (Hurler type) brain
[22,23] and α-iduronidase deﬁcient cats, dogs and mice [28–31]Fig. 1. Gangliosides GM3 and GM2 in brain from mouse models of several lysosomal
storage diseases. All mice were studied in the laboratory of one of us (MTV) using the
same procedure. Results are expressed in nmol ganglioside/g wet weight of tissue. WT:
wild type; PSAP: prosaposin deﬁciency; ctsd: cathepsin D deﬁciency (CLN10); Hex-0:
Hexosaminidase A + B deﬁciency (GM2-gangliosidosis, Sandhoff variant); NPC1: NPC1
deﬁciency (Niemann-Pick C); MPSI: α-iduronidase deﬁciency; MPSIIIb: α-N-acetylglu-
cosaminidase (NAGLU) deﬁciency; NPA: acid sphingomyelinase deﬁciency (Niemann-
Pick A); Hex-A: hexosaminidase A deﬁciency (GM2-gangliosidosis, Tay-Sachs variant).
Age at study varied from 1month to 10months, as indicated; Note that the GM2 level in
the Sandhoff mouse at 1 month of age is already higher than in the Tay-Sachs model at
10 months of age.(Fig. 1). In MPS I and MPS IIIB mice, ganglioside abnormalities appear
around 1month of age, and quantitatively, GM3 appearsmore affected
than GM2. Only few data exist regarding glycoproteinoses but deﬁnite
abnormalities have been reported for α-mannosidosis in the cat [29].
No increase was found in I-cell disease [32]. In many other lysosomal
and some non-lysosomal diseases, a small increase in the proportion
of GM2 and GM3 is often seen; however, this is usually more
conspicuous by immunocytochemical methods than by biochemical
measurement. This can be explained by the fact that biochemistry will
take into account the global amount of gangliosides, irrespective of its
subcellular localization, while immunocytochemistry can pinpoint
even tiny amounts, when present in vesicular structures in cells.
The availability of well characterized antibodies to GM2 and GM3
gangliosides, coupled with biochemical data described above indicat-
ing only aminimal presence of these two gangliosides in normal brain,
has meant that their localization in storage diseases could be
identiﬁed in individual cell types in brain, and indeed, to individual
vesicles within neurons. It has also been found that in some cases
probing tissues with antibodies fails to readily reveal individual
gangliosides in speciﬁc sites (e.g., the plasmalemma). This inaccessi-
bilitymost likely is due to the blocking action of associated proteins, or
simply because the ganglioside molecules do not occur in sufﬁcient
abundance to be labeled and identiﬁed. This cryptic feature of
gangliosides in terms of immunocytochemistry again indicates the
importance of combined biochemical and morphological techniques.
Immunostaining studies applied to lysosomal diseases undergoing
secondary lysosomal accumulation of GM2 and GM3 have consistently
shown that these gangliosides are sequestered in vesicles, appearing
as punctate, granular structures within the cytoplasm of cells. This
labeling has been documented in awide variety of lysosomal diseases,
including Niemann-Pick type A [Walkley, unpublished] and type C
(both NPC1 and NPC2 deﬁciencies) [15,33], MPS diseases including
type I, II, IIIA, VI, and VII [34,35], mucolipidosis type IV [36], several of
the Batten disorders, including CLN2 [Walkley, unpublished], CLN6
and CLN10 diseases [21], and α-mannosidosis [37,38]. In most such
diseases, GM2 and GM3 have been found to accumulate in a variety of
neurons and glia, with both gangliosides typically occurring within
the same cells. Many other patterns of staining, however, are also
evident. For example, in mice with Niemann-Pick C disease Purkinje
cells accumulate GM2 ganglioside but not GM3 [15]. In mice lacking
cathepsin D (CLN10 disease) it appeared that neurons accumulated
GM2 whereas glia primarily harbored GM3 storage [21]. In the
glycoproteinosis, α-mannosidosis, all neurons exhibited storage of
water soluble oligosaccharides as expected, whereas only scattered
numbers of pyramidal and GABAergic neurons in the cerebral cortex
also exhibited conspicuous accumulation of GM2 and GM3 ganglio-
sides [37]. As discussed later, this accumulation of gangliosides in α-
mannosidosis revealed a close correlation between the abnormal
presence of GM2 ganglioside in pyramidal neurons and ectopic
dendritogenesis, a phenomenon originally discovered in GM2 gang-
liosidosis [39] and now known to be unique to lysosomal diseases
with GSL storage.
The availability of appropriately ﬁxed tissues from large and small
animal models of lysosomal disease, coupled with immunoﬂuores-
cence and confocal microscopy, has permitted detailed analysis of the
subcellular localization of gangliosides. Unexpectedly, GM2 and GM3
gangliosides, while often being sequestered within the same neurons,
have been consistently found to reside in separate vesicle populations
in those cells [34,40] (Fig. 2). As described below, these labeled vesicles
also often occur independently of detectable amounts of unesteriﬁed
cholesterol visualized by ﬁlipin labeling. That GM2 and GM3 are not
co-sequestered has been interpreted to mean either that these
gangliosides are sequentially processed in separate compartments
within the endosomal/lysosomal system, or that these two ganglio-
sides are being generated by separate and independent processes, e.g.,
in synthetic vs. degradative compartments in cells [40,41].
Fig. 2. Gangliosides GM3 and GM2 and cholesterol in two adjacent cerebrocortical
neurons in murine MPS IIIA disease. Confocal analysis reveals the subcellular
localization of GM2, GM3, and cholesterol. A: GM2 immunoﬂuorescence. B: GM3
immunoﬂuorescence. C: Filipin histochemistry (for unesteriﬁed cholesterol). D:
Merged image. As is evident, most labeled vesicles in A and B contained either GM2
or GM3 gangliosides, but very few showed signiﬁcant co-labeling (D). While most
cholesterol also appeared to occur independently of ganglioside-containing vesicles,
GM3 ganglioside and cholesterol exhibited similar subcellular distribution, as shown by
the neuron on left (arrow). Note that the cell on the right in C (and D) does not exhibit
signiﬁcant cholesterol accumulation (it is largely ﬁlipin-negative). Scale bar in D equals
10 μm and applies to A–D. (From ref. 34, used with permission).
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been reported in lysosomal storage diseases such as globoid cell
leukodystrophy (Krabbe disease) [42] or the infantile type of CLN1
[43], where they seem to reﬂect invasion of the brain by cells of
mesenchymal origin, prominent astrogliosis or prominent loss of gray
matter (for CLN1 disease), rather than lysosomal dysfunction.
2.1.2. Glycosphingolipids in liver and spleen
With regard to secondary GSL storage in non-neural organs, only
few diseases with prominent hepatosplenomegaly have been studied
in detail. Interestingly, both the sphingomyelinase-deﬁcient types (A
and B) of Niemann-Pick diseases and Niemann-Pick type C again sharecommon features, with an increase of the major ganglioside in these
organs (GM3 in humans or cats, GM2 in mice) as well as several
neutral glycolipids, glucosylceramide, lactosylceramide, globotriao-
sylceramide and globoside [44–46]. GM3 is also typically increased in
liver and spleen from Gaucher disease [47,48]. Lactosylceramide
alterations in lysosomal storage diseases have recently been reviewed
[49]. Most prominent increases have been described in Niemann-Pick
diseases and prosaposin deﬁciency.
2.1.3. Free sphingoid bases
The pathophysiological role of free sphingoid bases, sphingolipid
metabolism intermediates normally present in minute amounts but
showing many-fold elevation in certain lysosomal diseases, may
have been underestimated and is currently being revisited (see
below). Sphingosine and sphinganine share the common feature
of a free amino group with lysosphingolipids. The latter have
been shown to be highly cytotoxic, and a speciﬁc increase of the
lysocompound corresponding to the main substrate for a defective
sphingohydrolase – and thus closely linked to the primary defect -
has been well documented in Krabbe [50–52] and Gaucher disease
[47,53,54], but was also reported in GM2 gangliosidosis [55,56],
metachromatic leukodystrophy [57], sphingomyelinase deﬁciencies
[6] and Fabry disease [58]. In Krabbe disease brain, galactosyl-
sphingosine is currently still considered as the primary offending
metabolite [59] (see below). With regard to free sphingoid bases, a
large increase was shown to occur in liver of the npcnih mouse and
of NPC patients [60–62]. This ﬁnding was recently extended to the
NPC1 cat model as well as to NPC2-deﬁcient patients and mouse
[Vanier and coworkers, unpublished data]. Subcellular fractionation
disclosed a lysosomal localization of the accumulated compounds
in NPC liver, and the sphingosine/sphinganine ratios indicated that
the compounds originated from sphingolipid degradation and not
biosynthesis [60,61]. Cultured skin ﬁbroblasts from classical NPC
patients also showed elevated amounts of these metabolites, and
data on phorbol ester binding suggested a deleterious effect on
protein kinase C (PKC) [63]. While in Niemann-Pick C disease the
sphingosine increase appeared disproportionately high in relation
with the concomitant sphingolipid increase, it did not appear
speciﬁc to this disorder, although few data are yet available [61,63].
However, only a very modest increase was observed in Niemann-
Pick C brain [at most 3 to 5-fold normal values in humans, mouse
and cat] compared to the 20–50 fold elevation occurring in liver or
spleen [61]; Vanier et al., unpublished data]. Biochemical data in
brain of other diseases are essentially lacking today. Further, the
lack of suitable antibodies for intermediate sphingolipid metabo-
lites has meant that more reﬁned studies using morphological
(confocal) techniques have not been possible. More recent studies
regarding the potential deleterious role of sphingoid bases in
Niemann-Pick C disease is discussed below [see section 3.2].
2.2. Cholesterol
From our current knowledge on the function of the NPC1 or NPC2
proteins, the prominent storage of unesteriﬁed cholesterol occurring
in liver and spleen tissue in Niemann-Pick C disease should be
considered as a primary consequence of the gene defect. In the liver,
interestingly, the mouse model accumulates much larger cholesterol
amounts (up to 8–10 fold the normal level) [64] than found in human
patients in biopsies or at autopsy (generally 2–3 fold the normal level)
[46]. An enhanced secretion of lipoproteins and increased lipid
synthesis has been demonstrated in NPC1-deﬁcient mouse hepato-
cytes [65] and studies in the mouse model suggest that the late
endosomal/lysosomal content of unesteriﬁed cholesterol correlates
with cell damage [64].On the other hand, the marked progressive
increase in cholesterol concentrations observed in liver and spleen of
patients with Niemann-Pick A or B is clearly secondary to the
Fig. 3. Filipin histochemical staining for unesteriﬁed cholesterol in cerebrocortical
neurons in multiple lysosomal diseases. A: Wt. (12 weeks old) B: MPS IIIA disease
(12 weeks old). C: Niemann-Pick disease type C (8 weeks old). D: GM1 gangliosidosis
(12 weeks old). Note that neurons in Wt brain exhibit no signiﬁcant ﬁlipin labeling of
somata, whereas in each of the lysosomal diseases there is substantial ﬁlipin labeling of
individual neurons. In MPS IIIA disease, some neurons are clearly more affected than
others, whereas in Niemann-Pick C and GM1 gangliosidosis all neurons are positive.
Filipin staining in GM1 was substantial and appeared to exceed that of Niemann-Pick C
in late stage disease. Calibration bar in C equals 12 μm and applies to all.
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to several lysosomal storage diseases is actually the coordination of
cholesterol metabolism with that of sphingomyelin and of glyco-
sphingolipids. Sphingomyelin levels correlate closely with the
amounts of cholesterol in different membranes and it has long been
hypothesized that the two lipids might form a complex. The presence
of sphingomyelin is also known to inﬂuence cholesterol movement
and its distribution among membranes [66]. Conversely, lysosomal
accumulation of unesteriﬁed cholesterol secondarily affects sphingo-
myelin metabolism (see below). More recently, it has further been
shown that cholesterol plays a major part in regulating trafﬁc of
sphingolipids along the endocytic pathway. Indeed, lysosomal
cholesterol overload correlates with abnormalities observed in
Niemann-Pick C cells, but quite unexpectedly, these studies also
showed that cholesterol homeostasis was perturbed in a number of
sphingolipidoses, secondary to sphingolipid accumulation [67,68].
Finally, free sphingoid bases, progesterone and many cationic
amphiphiles known to elicit drug-induced lipidoses have all been
shown to affect intracellular cholesterol trafﬁcking [69-73]. Indeed, a
signiﬁcant increase in cholesterol concentrations is typically part of
the storage pattern observed in drug-induced lipidoses in the
peripheral organs, but not in brain [74]. Similarly, and despite the
putative functions on cholesterol transport of the NPC1 and NPC2
proteins, biochemical studies in brain tissue from NPC patients or
mouse models have failed to demonstrate a signiﬁcant mass increase
of unesteriﬁed cholesterol. It has been argued that this might be
explained by the concomitant myelin loss. This is certainly a valid
argument for studies conducted on whole brain tissue, like those in
mice. However, by biochemical measurements, no signiﬁcant choles-
terol increase was found in dissected human gray matter from
patients, a result that should alleviate such a bias [13,75]. To a large
extent, this probably reﬂects the exclusive local source of brain
cholesterol [76–78], but also a possible imbalance between neuronal
bodies and distal axons [79] (see below).
While total cholesterol levels in brain are apparently not increased
in lysosomal diseases, in situ labeling using ﬁlipin histochemistry
reveals the presence of conspicuous sequestration of unesteriﬁed
cholesterol in individual brain cells (Fig. 3). This accumulation occurs
as storage-like granules in cell bodies of neurons and glia and has
been reported in awide spectrum of lysosomal diseases, including not
only Niemann-Pick C disease [15,33,80] but also GM1 and GM2
gangliosidosis, α-mannosidosis [81], as well as MPS I, II, IIIA, and VI
diseases [34,35]. In addition to cholesterol, each of these disorders
also exhibits either primary or secondary accumulation of GSLs,
suggesting some type of linkage between sequestration of these two
classes of compounds. Importantly, however, the accumulating
cholesterol as visualized with ﬁlipin labeling does not systematically
co-localize with each of the sequestered gangliosides. For example, in
MPS disease, while vesicular GM3 storage appears closely allied with
areas of ﬁlipin labeling in cells, GM2 does not reveal a similar
association (Fig. 2). For Niemann-Pick type C disease in which defects
in the cholesterol-binding proteins, NPC1 or NPC2 are causative [15],
cholesterol is believed to be sequestered as a result of an induced
block in its retroendocytic movement from late endosomes and
lysosomes to other sites in the cell [82]. The presence of accumulating
unesteriﬁed cholesterol in the cell bodies of neurons and glia in brain,
in view of the absence of increases in total cholesterol (as described
above), have suggested possible shifts in the distribution of the
cholesterol rather than absolute increases. Evidence for this can be
found in studies examining cholesterol localization in neuronal cell
bodies vs. axons in culture which appear to show elevated perikaryal
cholesterol but decreased axonal cholesterol [79]. Such ﬁndings, as
well as others described below suggestive of functional cholesterol
deﬁcits in NPC disease, indicate that the abnormal sequestration of
materials in lysosomal disease may have signiﬁcant consequences for
neuron function.As described above, cholesterol sequestration in Niemann-Pick C
disease is also accompanied by accumulation of GSLs, including GM2
and GM3 gangliosides. Abnormal cholesterol sequestration was
reported to be already present in the brain of 9 days-old npc1mutant
mice [80]. In the latter study, no ganglioside increase could be
demonstrated at this age. However, signiﬁcantly increased levels of
GM2 ganglioside were repeatedly documented in the brain of 10-
days-old mice in the authors' laboratories (see above, section 2.1). In a
manner remarkably similar to that reported for MPS disease [34],
immunocytochemical studies of neurons in Niemann-Pick C have
revealed the presence of GM2 and GM3 gangliosides in independent
populations of vesicles which in turn (particularly for GM2) have very
little overlap with cholesterol-sequestering vesicles [Walkley et al.,
unpublished]. Interestingly, while this GM2 and GM3 accumulation
has generally been considered to occur secondary to cholesterol
storage in NPC disease, two independent studies have nonetheless
shown that limiting expression of complex gangliosides in this
condition dramatically reduces this intracellular cholesterol seques-
tration in neurons lacking NPC1 [83,84]. In both cases this work was
carried out using double mousemutants lacking the NPC1 protein and
GalNAc transferase, the enzyme responsible for synthesis of all
complex gangliosides beyond GM3 and GD3, accompanied by ﬁlipin
staining to reveal intraneuronal sequestration of cholesterol. Thus
while this and related GSL synthetic mutants, as well as this double
mutant, lacks demonstrable impact on cholesterol homeostasis
overall [85], the types of gangliosides expressed by neurons lacking
NPC1 appear to ultimately dictate the degree of intraneuronal
cholesterol sequestration [83,84], Walkley et al,, unpublished.
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The two phospholipids of particular interest in the context of this
review are sphingomyelin and bis(monoacylglycero)phosphate
(BMP), also named (quite incorrectly) lysobisphosphatidic acid
(LBPA) by some authors, an anionic phospholipid enriched in internal
membranes of multivesicular endosomes and lysosomes [86]. A
striking accumulation of BMP was ﬁrst described in liver and spleen
of patients with Niemann-Pick disease type A [87] a ﬁnding extended
to Niemann-Pick B and C [10,46,75, 88,89]. BMP is also a major
component of the storage in non–neural organs of drug-induced
lipidosis [90], but no major increase has been found to occur in
Gaucher disease. Data regarding BMP in brain are lacking for most
lysosomal diseases. A small increase had been reported in the brain of
patients with infantile NCL (CLN1) [91,92], and a signiﬁcant elevation
was recently found in the brain of the cathepsin D deﬁcient mouse
(model of CLN10) [21]. Interestingly, in Niemann-Pick diseases A or C
(as well as in drug-induced lipidosis), no noticeable elevation of the
concentration of BMP has been found in brain [15,87,93].
Historically, all sphingomyelin-storage diseases were included
under the eponym “Niemann-Pick disease”, until the early eighties
and the seminal discovery by the group of P. Pentchev demonstrat-
ing abnormal intracellular trafﬁcking of cholesterol in Niemann-Pick
C disease. Early work by Crocker and Farber [94] had already
pointed out that liver and spleen from patients with types C and D
showed much less sphingomyelin storage than those with types A
and B. It nevertheless took a long time to clearly demonstrate that
in Niemann-Pick C (now including type D) disease sphingomyelin
accumulation is secondary to lysosomal cholesterol storage. The
ﬁrst piece of evidence came from studies in cultured ﬁbroblasts
from patients showing that the typical partial deﬁciency of
sphingomyelinase activity could be modulated by the presence or
absence of LDL in the cultivating medium [95,96], and this is also
supported by comparative studies of cholesterol and sphingomyelin
in liver from type A and type C foetuses (Fig. 4). Note than in
human Niemann-Pick type C disease, sphingomyelin accumulation
remains very moderate in liver and is much higher in spleen [46],
while liver is a major site of accumulation in the mouse models
[15]. Very importantly, no secondary increase of sphingomyelin has
so far been described in brain for any lysosomal storage disease
(including Niemann-Pick C), and this does not occur either in drug-
induced lipidoses.Fig. 4. Lipid storage in liver from 20week-old foetuses with Niemann-Pick type A (NPA)
(3 cases) and type C (NPC) (3 cases) diseases. This was compared to concentrations in
foetuses with lysosomal disorders not affecting the liver (controls, 5 cases). All results
are expressed as mean values for each group. In NPA, the primary stored lipid,
sphingomyelin, is already very elevated, and is accompanied by a prominent secondary
increase of cholesterol. In NPC, massive cholesterol storage occurs, with a modest
sphingomyelin increase.3. Mechanisms and consequences of secondary storage
3.1. Complex mechanisms underlie heterogeneous substrate
accumulation in lysosomal disease
As outlined above, many studies have revealed that the types of
sequestered compounds and their distribution in lysosomal disease
are marked by heterogeneity and in most cases no clear connection
has yet been established between the primary lysosomal defect and
the sequestration of secondary compounds that become involved in
the storage process. Of particular focus here is the accumulation of
GSLs, phospholipids, and unesteriﬁed cholesterol across a wide
spectrum of lysosomal disease. Given that a principal role of the
endosomal/lysosomal system is to degrade and recycle substrates
derived from the cell surface by endocytosis and from inside the cell
by way of autophagy, it would only be logical that single lysosomal
protein defects might lead to overall dysfunction of this system and
therefore to storage of multiple substrates. It might also be argued that
these multiple substrates would be comingled within the same
individual storage bodies accumulating within cells, a view supported
by early work on Tay-Sachs disease. Cell fractionation studies of brain
tissue from Tay-Sachs disease examining components in the fraction
enriched in storage bodies (membranous cytoplasmic bodies) showed
one third of the dry weight to be ganglioside, mostly GM2 (but also
detectable amounts of asialo-GM2, lactosylceramide, and glucocer-
ebrosides. Parallel ﬁndings were also reported for GM1 gangliosidosis
[97]. Later studies similarly revealed evidence that cytosomes in Tay-
Sachs disease were characterized by accumulation of not only GM2
ganglioside but also phospholipids, cerebrosides, sphingomyelin,
cholesterol and cholesterol esters, and so forth [Reviewed in 98].
While these biochemical studies could be interpreted to suggest that
all storage components in lysosomal disease were co-sequestered
within the same individual storage vesicles, the use of electron
microscopy consistently demonstrated a signiﬁcant degree of hetero-
geneity in the ultrastructure of cytoplasmic storage bodies. The latter
ﬁnding is consistent with a differential or uneven distribution of
individual storage materials. This heterogeneity of storage at the
subcellular level has been further elucidated using modern confocal
and immunoﬂuorescence methods. For example, as described earlier,
in MPS disease neurons accumulate not only the primary glycosami-
noglycan (GAG) storage compounds secondary to individual lysoso-
mal enzyme defects but also GM2 and GM3 gangliosides and
unesteriﬁed cholesterol [34]. Importantly, these multiple substrates,
as shown by ﬂuorescent markers and confocal microscopy, are not all
systematically co-localized within single types of storage vacuoles
(Fig. 2). For example, the GM2 and GM3 gangliosides that accumulate
in a host of lysosomal diseases largely reside in separate compart-
ments within the cell, with GM2 showing minimal, if any, co-
sequestration with cholesterol. This is similarly true in neurons
affected by Niemann-Pick C disease inwhich cholesterol accumulation
is believed primary and ganglioside sequestration secondary [Walkley
et al., unpublished]. Even the primary storage compound in MPS IIIa
disease, heparan sulfate, does not appear consistently co-sequestered
with each secondary storage compound [34].
It might be argued that such secondary sequestration of materials
in neurons is of little real signiﬁcance, since it occurs downstream
from the primary disease event. However, the tight correlation
between some speciﬁc features in the pathogenic cascade (e.g.,
ectopic dendritogenesis) and involvement of particular classes of
secondary storage materials (in this case GSLs, particularly GM2
ganglioside) [29], provide clear evidence that understanding why
secondary storage events occur likely holds important insight for
these diseases as a whole. In thinking about why the defective
function of a single lysosomal enzyme or other protein could lead to
storage of multiple substrates, several possible mechanisms can be
suggested. These could include inhibition of lysosomal enzymes by an
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of the internal environment of late endosomes and lysosomes (pH
change, lack of saposin-substrate interaction, etc.) leading to reduced
degradation of additional substrates. It is also conceivable that
lysosomal storage may in some manner compromise the egress of
substrates from late endosomes/lysosomes leading to prolonged
persistence at this site. Additionally, sequestration of compounds may
disrupt normal trafﬁcking or fusion of vesicles in the extended
endosomal pathway, including early endosomes, recycling endosomes
as well as late endosomes. This could result in compromise in
movement of a variety of materials to sites for further degradation.
Finally, induction of autophagy, or its blockage, may further
complicate vesicle fusion and trafﬁcking events. All of these mechan-
isms have been suggested to contribute to sequestration of materials
in different lysosomal diseases. Understanding precisely which of
these events occurs in a given lysosomal disease is important since
one mechanism versus another may provide insight into additional
downstream consequences, from induction of dendritogenesis to
formation of axonal spheroids, two key features of the cellular
pathology of many lysosomal diseases. Such understanding may also
reveal close linkage between different types of lysosomal diseases,
including issues of importance for therapy.
One of the earliest mechanisms explored as a cause of secondary
storage of gangliosides (e.g., GM2, GM3, and GD3) was in MPS disease
and involved the possibility that accumulating GAGs were binding to
and inhibiting the activity of several additional lysosomal hydrolases.
One early study [99] demonstrated partial deﬁciencies of β-galacto-
sidase, α-galactosidase, and arylsufatase A in the livers of patients
with MPS disease, possibly as a result of secondary GAG binding and
isoelectric points being made more acid. Experimentally mixing
chondroitin sulfate and β-galactosidase also diminished its activity
providing further support to this view. Similar results were reported in
another study showing that 21 different lysosomal enzyme activities
in leukocytes were strongly inhibited by mixing them in vitro with
various GAGs, with the mechanism again believed to be possibly
secondary to GAG-enzyme binding [100]. A third study showed that
neuraminidase activities toward GD1a, GD3 and GM3 were dimin-
ished in ﬁbroblasts of MPS diseases, possibly due to binding of sulfated
GAGs with the enzyme [101]. While a plausible mechanism for
disrupting ganglioside degradation, it is not readily apparent why
different MPS disorders with different types of GAG storage each
result in storage of essentially the same pattern of gangliosides. As
described earlier, this accumulation consists primarily of GM2 and
GM3 gangliosides, yet blockage of GM2 degradation would in itself
suggest the presence of less GM3. While inhibition of neuraminidase
could explain the GM3 elevation, β-hexosaminidase (for degrading
GM2 ganglioside) has not been reported to be inhibited in the MPS
diseases. Similarly, GM1 has not been reported to accumulate in spite
of the reported sensitivity of β-galactosidase to the proposed GAG-
induced inhibition. Finally, the pattern of GM2 and GM3 sequestration
in separate vesicles [34] is not readily explained by a generalized
enzyme inhibition mechanism, but oddly, is also found in other
lysosomal diseases (without known GAG storage) [40]. These studies
raise signiﬁcant questions about whether GAG-induced inhibition of
lysosomal enzymes is occurring in vivo as the mechanism underlying
ganglioside storage in MPS disease.
As mentioned earlier, lysosomal cholesterol homeostatic events
have been found to be a signiﬁcant aspect not only in Niemann-Pick C
cells, but also in a number of sphingolipidoses, secondary to
sphingolipid accumulation [67,68]. Given that cholesterol and glyco-
sphingolipids, as well as sphingomyelin, are constituents of mem-
brane specializations referred to as “rafts” has led to the provocative
view that lysosomal diseases may be essentially collections of non-
degraded rafts constituents within lysosomes [102]. In diseases like
Niemann-Pick C, cholesterol accumulation is believed to appear ﬁrst,
as a result of defective function of the NPC1 or NPC2 proteins, and tobe subsequently accompanied by GSL sequestration. In GM1 or GM2
gangliosidosis, the ganglioside storage would presumably be the
initial event, followed by cholesterol sequestration. The extent to
which this primary vs. secondary accumulation drives subsequent
steps in the disease cascade is not clearly understood. Importantly,
recent studies of NPC cells, and cells treated with U188666A, which is
believed to mimic NPC disease [69], failed to show an alteration in the
raft to non-raft membrane ratio, a ﬁnding believed to argue against
the raft accumulation hypothesis [103]. This ﬁnding is also consistent
with the confocal microscopy studies described earlier which indicate
a signiﬁcant degree of separation of cholesterol/GSL storage compo-
nents within vesicular domains of lysosomal disease-affected neurons
[34]. What was found in the in vitro studies instead of evidence for
raft accumulation, was that cholesterol (and presumably any
accompanying GSLs), leads to an inhibition of intra-endosomal
membrane dynamics. Importantly, these intraluminal vesicles are
believed critical for degradative processing, during which time in
normal cells, the content of unesteriﬁed cholesterol has been shown
to decrease while the negatively charged phospholipid, BMP,
increases. Efﬁcient degradation of GSLs at these sites requires, in
addition to an acidic pH, water soluble hydrolases, sphingolipid
activator proteins and anionic phospholipids like BMP [104]. The focus
on abnormalities at the intra-endosomal membrane is further
supported by the ultrastructure of storage vacuoles in NPC disease,
known as polymembranous cytoplasmic bodies, which in essence
resemble abnormal multivesicular bodies (i.e., late endosomes)
[15,105]. Along this same line is the ﬁnding that in NPC ﬁbroblasts,
high cholesterol levels markedly impaired the normal co-localization
of glucosylceramidase, saposin C and BMP and altered both the
stability and activity of the enzyme [106]. Interestingly, recent studies
have also revealed that exogenous application of BMP (LBPA) to cells
with the NPC cellular phenotype has the ability to reverse the
cholesterol accumulation [107].
3.2. Consequences of lysosomal storage
To a certain extent the question posed here – What are the
consequences of secondary lipid storage in lysosomal disease? – is
applicable to not just secondary events, but also to primary storage.
For example, correlations have been drawn above between secondary
storage of GM2 ganglioside in diseases likeα-mannosidosis andMPS I
disease and ectopic dendritogenesis [29,108]. Yet, this remarkable
phenomenon was discovered in Tay-Sachs and related GM2 gang-
liosidoses [39] in which the storage of GM2 is the primary event.
Therefore, the correlation between GM2 sequestration and the
induced growth of ectopic dendrites suggests that the reason for the
GM2 elevation may not matter. Rather it is the involvement of GM2
and related GSLs, coupled with lysosomal dysfunction, that appear in
someway to stimulate new dendrite growth, not whether the cause of
the GM2 elevation is primary or secondary. But how might such an
alteration in GLS catabolism, synthesis, or localization lead to
downstream consequences of disease such as ectopic dendritogen-
esis? A parallel question can be raised for cholesterol, that is, is there
evidence that its sequestration in lysosomal disease directly relates to
pathogenesis? The possible deﬁcit of cholesterol in axons secondary to
somatic sequestration [79], mentioned earlier, surely would have
consequences on myelination and action potential propagation. In the
Niemann-Pick C disease mousemodel the sequestration of cholesterol
also appears to lead to deﬁcient production of the cholesterol-derived
neurosteroid, allopregnanolone [109]. Presumably, this occurs as a
result of the blockage of cholesterol movement out of late endosomes
to mitochondria where enzyme systems are present for neurosteroid
biosynthesis. This ﬁnding suggests that one aspect of the pathogenic
cascade in lysosomal disease may relate to deﬁciency conditions,
rather than simple overabundance of stored compounds [41]. An
unanswered question related to this ﬁnding is whether the
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outcome. That is, in other conditions, like GM1 or GM2 gangliosidosis
in which signiﬁcant cholesterol sequestration also occurs (here not
primary but clearly secondary to ganglioside storage) is allopregna-
nolone synthesis similarly compromised?
These types of complex events involving primary and secondary
lipid accumulation in lysosomal disease clearly suggest that it is not
simply dysfunction of the lysosome that is central to pathogenesis,
but rather that the entire endosomal/lysosomal system, and its
salvage pathways, is in some manner compromised. Endocytosis,
along with involvement in regulating the expression of components
of neuronal membranes through, for example, the internalization of
receptor-ligand complexes, also plays a critical role in attenuating
and integrating a wide variety of signaling events affecting many
cellular functions [110]. Endocytic events in neurons govern a variety
of signaling mechanisms, from those linked to growth factors to
neurotransmitters. Growth factor receptors are internalized by
endocytosis in neurons, both in the axonal and soma-dendritic
domains and signaling events are believed dependent on the
speciﬁcs of the endocytic route and vesicle type [111]. The ﬁnding
that growth factors like brain-derived neurotrophic factor (BDNF), a
TrkB ligand, when applied to young cortical neurons cause exuberant
dendrite growth [112] raises the question of whether growth factor
signaling might be abnormal in lysosomal disease as a result of
ganglioside sequestration and thus account for the phenomenon of
ectopic dendritogenesis. There is indeed one published work
suggesting that Trk B signaling in Niemann-Pick C disease may be
abnormal [113].
Endocytic mechanisms are also known to control the availability of
neurotransmitter receptors at excitatory synapses. AMPA (α-amino-
3-hydroxy-5-methylisoazole-4-proprionic acid) receptors, which reg-
ulate the majority of fast excitatory neurotransmission and are
therefore critical for synaptic plasticity, are known to undergo rapid
constitutive internalization as a consequence of synaptic activity. Once
internalized, AMPA receptors are sorted from early endosomes to
either specialized recycling endosomes for re-insertion in the
plasmalemma or, are trafﬁcked to late endosomes for fusion with
lysosomes and resulting elimination [114,115]. Subunits forming
AMPARs (GluR1-4) are well documented to assemble as homo- or
hetero-dimers, with subunit composition being critical for their
functional properties. The GluR2 subunit, unlike GluR1, 3 and 4, is
Ca2+-impermeable, making it the key determinant of AMPAR function
[116]. Importantly, over-expression of the GluR2 subunit in cultured
neurons induces ectopic dendritic spine formation, consistent with
AMPA receptor expression and localization playing a major role in
dendrite and synapse plasticity [117]. These ﬁndings suggest that the
endosomal/lysosomal system, through control of AMPA receptor
availability, is positioned to have signiﬁcant inﬂuence over dendritic
plasticity and raise the question of whether GSL accumulation in early
or recycling endosomes is affecting this mechanism and causing
ectopic dendritogenesis in lysosomal disease [41].
In addition to possible signal transduction derangements sec-
ondary to ganglioside accumulation in the endosomal/lysosomal
system, other major consequences of secondary lipid sequestration
can also be raised. For example, does “leakage” or altered trafﬁcking
of gangliosides out of the endosomal/lysosomal system to other sites
in the cell normally devoid of signiﬁcant levels of gangliosides (e.g.,
the endoplasmic reticulum) cause consequences for neuron func-
tion. It has been proposed, for example, that in GM1 gangliosidosis
that the GM1 ganglioside mislocalizes to membrane domains
normally containing little or no ganglioside, like the ER, resulting
in depletion of Ca++ stores, activation of the ER stress response and
eventually apoptosis and neuron death [118]. Similarly, in GM2
gangliosidosis it has been shown that GM2 ganglioside increases in
microsomal membranes and inhibits the activity of SERCA, which in
turn has the capacity to cause ER stress and apoptosis [119]. Parallelevents in dysregulation of intracellular stores of Ca++ secondary
to inappropriate ganglioside buildup in internal cell membranes
may similarly be occurring in Gaucher, Niemann-Pick A and other
lysosomal diseases.
A second issue in terms of the consequences of storage is whether
the accumulating compounds are themselves toxic to the cells
resulting in acute cell death. The best example here is the psychosine
(galactosylsphingosine) hypothesis in Krabbe disease [see for review,
59]. Minute amounts of this compound have been shown to be
aberrantly synthesized by oligodendrocytes. Normally psychosine will
be degraded by galactosylceramidase. In Krabbe disease, in which this
enzyme is deﬁcient, galactosylsphingosine levels progressively
increase, and assumedly the local concentration soon reaches a toxic
level, resulting in dysfunction and ﬁnally death of the oligodendro-
cyte. This explains why galactosylceramide accumulates only in
globoid cells and to a globally very minor amount. The cytotoxicity
of this compound has been well established, but despite a number of
studies following the hypothesis of Hannun and Bell on PKC inhibition
[120], the exact mechanism remains unclear and is probably complex.
While all experimental data seem to conﬁrm the role of galactosyl-
sphingosine in pathogenesis of Krabbe disease, that of other lyso-
sphingolipids appear much weaker, with the notable exception of
glucosylsphingosine in Gaucher neurons [see 59 for review]. The
potential pathogenic role of free sphingoid bases in Niemann-Pick
type C has recently been revisited. In NPC1 ﬁbroblasts, one group
showed hypophosphorylation of vimentin as a result of PKC inhibition,
leading to entrapment of rab9 and alterations in lipid trafﬁcking [121].
In a very recent paper [122], NPC1-mutant cells were found to have a
large reduction in the acidic compartment calcium store compared to
wild-type cells. The authors conclude that sphingosine storage is an
initiating factor in NPC1 disease pathogenesis that causes altered
calcium homeostasis, leading to the secondary storage of sphingoli-
pids and cholesterol. [122]. No data, however, are so far available from
neuronal cells, which are the primary target in the disease and store
much lesser amounts of free sphingosine.
In terms of neuron death, mentioned above, it is recognized that
lysosomal diseases are typically referred to in the literature as neur-
odegenerative. The actual role of neuron death, however, in clinical
disease onset and progression is not well established. In most cases
individuals with lysosomal disease appear normal in early life and
only subsequently exhibit loss of developmental milestones or, if later
onset, changes in cognition, behavior, motor/sensory function, and so
forth. The extent to which death of neurons per se underlies this
clinical change is not known and deserves greater study. Importantly,
there is ample evidence indicating that neurons can survive for years,
indeed decades, with some level of intraneuronal storage in lysosomal
disease, so the storage process itself need not be acutely cytotoxic. It
may well be the host of pathogenic cascade events, from signal
transduction defects to deranged features of dendrites and axons that
largely underlie chronic neuronal dysfunction. This question is made
all the more relevant by therapeutic attempts designed to alleviate
microglial activation and thereby, presumably, reduce the elimination
of damaged neurons. This may or may not prove neurologically
beneﬁcial. On the other hand, selective neuronal vulnerability also is
evident in lysosomal diseases, with Purkinje cell loss in the cerebellum
in Niemann-Pick C disease perhaps being one of the best examples. It
has been argued elsewhere that Purkinje cell death may be secondary
to axonal spheroid formation, a predominant feature of the cellular
pathology of this neuron not only in Niemann-Pick C but also other
lysosomal diseases [123]. But what renders Purkinje cells so vulner-
able to this event? While in Niemann-Pick C Purkinje cells are known
to accumulate cholesterol and GM2 ganglioside, these same neurons
in other storage diseases (e.g., α-mannosidosis) with this exact same
pattern of cell loss, accumulate other materials, arguing for a more
generic defect in endosomal/lysosomal function as the cause. In this
case, knowledge of the secondary lipid storage components in the
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early.
Yet a third possible mechanism leading to compromise in cell
function is whether the sequestration of materials within neurons,
e.g., simple gangliosides like GM2 and GM3, are leading to states of
induced “starvation” secondary to the sequestration of precursors for
GSL synthesis. This possibility is somewhat parallel to the studies
mentioned earlier which report allopregnanolone deﬁciency in
Niemann-Pick C mice secondary to cholesterol sequestration [109].
GSLs may represent a second class of compounds impacted by
sequestration of metabolic precursors, a view suggested many years
ago by Sandhoff et al, [124]. This provocative idea draws support from
the ﬁnding that 70–90% of the GSL pool in neurons is salvaged prior to
complete degradation in the endosomal/lysosomal system [125]. Thus
the sequestration of gangliosides like GM1, GM2, or GM3 in lysosomal
disease may result in a deﬁcit of precursor material in the Golgi/TGN
for renewal of complex gangliosides at the plasmalemma. A possible
consequence of such an event is an up-regulation GSL synthesis, an
event that in turn could alter the expression of speciﬁc gangliosides or
related components of membrane rafts in the plasmalemma. Such
enhanced GSL synthesis likely would not solve the neuron's deﬁcit in
precursor material, however, but rather would simply add further to
the storage process. Yet another possible solution to metabolic
precursor deﬁcits might be for the neuron to “mine” resources within
the cell through a mechanism known as macroautophagy. Recent
studies have shown that maintaining a basal level of autophagy is
critical for normal neuronal function [126,127] so in this respect they
are not really different from other cells in which starvation-induced
stress elicits autophagy [128]. The involvement of autophagy in
lysosomal disease has recently come under increased focus [129-132],
with current reports supporting both induction and blockage.
Presumably, blockage in autophagy would be detrimental to neurons,
given their reliance on this mechanism, but even if autophagy is
increased, this again may not provide beneﬁt since ultimately the
same primary catabolic defect, at least in the case of lysosomal
enzyme deﬁciencies, would limit degradation of the stored ganglio-
sides in the autophagolysosomes.
4. Secondary storage compounds as biomarkers to evaluate therapy
The secondary increase in brain gangliosides GM2 and GM3 has
been used as a biomarker to evaluate efﬁcacy of gene therapy by
intracerebral injection of an adeno-associated virus (AAV) coding for
the defective enzyme in the MPS1 models of mouse and dog [133,134]
and MPSIIIB and MPS VII mice [135,136], and of bone marrow
transplantation in the feline MPSI model [31]. An excellent correlation
was found between the reduction or normalization of these markers
and the amelioration of primary biochemical markers or clinical
features. Similarly, the beneﬁcial effect of injection at 7 postnatal days
of allopregnanolone in β-cyclodextrin in the npcnih mouse was
reﬂected by a signiﬁcant decrease in the proportion of these two
gangliosides [109]. The secondary increase of minor brain gangliosides
thus appears as a good biomarker for monitoring of therapeutic
efﬁcacy in animal models of a number of lysosomal storage diseases. A
major limitation is that brain tissue analysis is not applicable to live
patients. No study has been published regarding the levels of these
gangliosides in cerebrospinal ﬂuid of human patients with mucopo-
lysaccharidoses or NPC. Using tandem mass spectrometry, minute
amounts of compounds can now be reliably measured. However,
whether the detected changes would reﬂect what happens in brain
tissue remains unknown. The relevance to neuropsychological
manifestations of lipid markers in plasma, such as increases of
glucosylceramide in NPC patients [45], of GM3 in Gaucher patients
[48], or modiﬁcations in the pattern of BMP species recently reported
for several lysosomal diseases [137] may be even more limited.
Although a considerable effort is currently pursued, as of today, thelack of suitable biomarkers constitutes a major problem for clinical
trials in lysosomal diseases affecting the central nervous system.
5. Conclusions
Lysosomal diseases are complex conditions caused by awide range
of gene and protein defects and characterized by intracellular
sequestration of multiple substrates, including GSLs, phospholipids
and cholesterol. Some of these storage materials bear no direct
relation to the primary metabolic defect and are therefore considered
as secondary, yet ample evidence suggests they nonetheless play key
roles in disease pathogenesis. GSLs, for example, are characteristically
increased in a number of lysosomal diseases without primary defects
in GSL catabolism and the intraneuronal accumulation of GM2
ganglioside correlates with ectopic dendritogenesis, a phenomenon
unique to lysosomal disease. Cholesterol accumulation also occurs
along with GSLs in many lysosomal diseases and evidence suggests
that it may interfere with normal endosomal/lysosomal processing as
well as lead to cholesterol deﬁcits elsewhere in neurons, with
consequences for neuronal function. Fully understanding the types,
the cellular and subcellular locations, and the reasons for sequestra-
tion of the many secondary storage compounds characterizing
lysosomal disease is critical for the full elucidation of the cell biology
of these conditions, and may also provide new clues for biomarker
identiﬁcation and therapeutic advances.
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